health care

There seems to be an inclination among policy-makers that adherence to evidence-based policy-making is a luxury we can only afford when not in a crisis.

As of now, every bit of COVID-19 good news is being buried or tainted with doubts.

Clinical trials do more than inform us whether a drug is effective. They inform us when a drug is effective, in what combinations, in what dosages, and what are the counter indications.

We have experienced unprecedented economic effects of the COVID-19 pandemic and social distancing policies. Twenty two million Americans lost jobs in four weeks.

Due to coronavirus, governments across the globe are considering and/or are doing something they certainly could not do before: implement mass surveillance programs to track COVID-19 patients.

We have yet to record meaningful samples of the general population with regard to the prevalence of coronavirus, the distribution of its outcomes, and the build-up of immunity.

The coronavirus crisis will be considered one of the most important global events of the early decades of the 21st century.

If the COVID-19 crisis has taught us one thing—aside from the need to wash your hands often—it is that the FDA’s approval process for much-needed medicine to those with debilitating and terminal diseases is in dire need of reform.

The United States has taken unprecedented actions to halt the spread of the novel coronavirus and the illness it causes, COVID-19. How bad will this be for the economy?

In its first decade, ObamaCare has failed to solve many of the health care problems it was supposed to address.

The word has leaked out on a potential cheap treatment for COVID-19, the antimalarial drug hydroxychloroquine.

Here’s what Trump should say during his next coronavirus press conference.

The stimulus approach fails to address the fundamental causes of the economic downturn, while it balloons the deficit to no good end.